Get the Stockscreener App
65.93
0.38%
0.25
Pre-market:
66.23
0.30
+0.46%
Haemonetics Corp stock is traded at $65.93, with a volume of 627.69K.
It is up +0.38% in the last 24 hours and up +5.84% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$65.68
Open:
$65.37
24h Volume:
627.69K
Relative Volume:
0.75
Market Cap:
$3.31B
Revenue:
$1.36B
Net Income/Loss:
$123.81M
P/E Ratio:
27.36
EPS:
2.41
Net Cash Flow:
$20.35M
1W Performance:
-1.89%
1M Performance:
+5.84%
6M Performance:
-13.35%
1Y Performance:
-13.64%
1-Day Range:
$65.28
$67.50
1-Week Range:
$65.07
$70.13
52-Week Range:
$58.80
$97.97
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
65.93 | 3.31B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
How Do Investors Really Feel About Haemonetics? - Benzinga
Haemonetics at Raymond James Conference: Strategic Growth Insights - Investing.com
Haemonetics at Raymond James Conference: Strategic Growth Insights By Investing.com - Investing.com UK
Haemonetics Names Chief Operating Officer, Chief Commercial Officer -March 03, 2025 at 05:40 pm EST - Marketscreener.com
Haemonetics appoints new executive leadershi - Investing.com
Haemonetics Announces Executive Leadership Updates - Quantisnow
Global Blood Bank Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight - GlobeNewswire Inc.
Haemonetics Corp. to Host Earnings Call - ACCESS Newswire
Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference - Quantisnow
Zacks Research Forecasts Haemonetics’ Q3 Earnings (NYSE:HAE) - Defense World
Van ECK Associates Corp Buys Shares of 39,620 Haemonetics Co. (NYSE:HAE) - Defense World
Haemonetics FY2025 EPS Forecast Decreased by Zacks Research - Defense World
(HAE)Analyzing Haemonetics's Short Interest - Benzinga
SG Americas Securities LLC Decreases Stock Holdings in Haemonetics Co. (NYSE:HAE) - MarketBeat
Janney Montgomery Scott LLC Invests $402,000 in Haemonetics Co. (NYSE:HAE) - MarketBeat
Haemonetics (NYSE:HAE) Reaches New 12-Month Low After Analyst Downgrade - MarketBeat
Haemonetics Co. (NYSE:HAE) Shares Sold by Retirement Systems of Alabama - MarketBeat
Haemonetics Co. (NYSE:HAE) Shares Sold by Yousif Capital Management LLC - Defense World
Haemonetics' (NYSE:HAE) Earnings Offer More Than Meets The Eye - Yahoo Finance
Haemonetics Co. (NYSE:HAE) Receives $101.67 Average Price Target from Analysts - MarketBeat
Haemonetics (NYSE:HAE) Given New $108.00 Price Target at Needham & Company LLC - MarketBeat
Haemonetics Co. (NYSE:HAE) Receives $101.67 Consensus Target Price from Analysts - Defense World
Haemonetics (NYSE:HAE) Price Target Cut to $100.00 by Analysts at JMP Securities - MarketBeat
Haemonetics (NYSE:HAE) Raised to "Buy" at StockNews.com - MarketBeat
Haemonetics (NYSE:HAE) Downgraded to Underperform Rating by Bank of America - MarketBeat
Haemonetics' (HAE) "Strong-Buy" Rating Reaffirmed at Raymond James - MarketBeat
Haemonetics (NYSE:HAE) Reaches New 52-Week Low After Analyst Downgrade - Defense World
Barrington Research Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price - MarketBeat
Haemonetics’ (HAE) “Strong-Buy” Rating Reiterated at Raymond James - Defense World
Haemonetics (NYSE:HAE) Upgraded at StockNews.com - Defense World
Haemonetics (NYSE:HAE) Shares Gap Down Following Weak Earnings - MarketBeat
It is Poised to be a Bull Market for Haemonetics Corp (HAE) - SETE News
Haemonetics (HAE) Projected to Post Earnings on Thursday - MarketBeat
Haemonetics (NYSE:HAE) Releases FY 2025 Earnings Guidance - MarketBeat
Haemonetics (NYSE:HAE) Receives “Strong-Buy” Rating from Raymond James - Armenian Reporter
Haemonetics Co. (NYSE:HAE) Sees Large Increase in Short Interest - MarketBeat
Haemonetics (HAE) Q3 Earnings Meet Estimates - MSN
Haemonetics Corp [HAE] Former Officer makes an insider purchase of 6,238 shares worth 0.57 million. - Knox Daily
Haemonetics' stock slides on revenue miss - MSN
Needham & Company LLC Lowers Haemonetics (NYSE:HAE) Price Target to $108.00 - Armenian Reporter
Haemonetics Corporation (NYSE:HAE) Q3 2025 Earnings Call Transcript - Insider Monkey
Haemonetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Haemonetics Corp (HAE) Q3 2025 Earnings Call Highlights: Strong Hospital Growth Amid Plasma Revenue Challenges - GuruFocus.com
Haemonetics (NYSE:HAE) Shares Gap Down After Earnings Miss - Defense World
Haemonetics Corp (HAE) Q3 2025 Earnings Call Highlights: Strong Hospital Growth Amid Plasma ... - Yahoo Finance
Haemonetics Corp (HAE) Q3 2025 Earnings Call Highlights: Strong Hospital Growth Amid Plasma ... By GuruFocus - Investing.com Canada
Boston Trust Walden Corp Has $71.50 Million Position in Haemonetics Co. (NYSE:HAE) - MarketBeat
Earnings call transcript: Haemonetics Q3 2024 sees EPS beat, stock drops - MSN
FY2025 EPS Estimates for Haemonetics Reduced by Analyst - MarketBeat
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):